role
lipid
metabolit
prostaglandin
eicosanoid
ep
receptor
ep
underli
proinflammatori
mechanist
aspect
burkitt
lymphoma
nasopharyng
carcinoma
cervic
cancer
prostat
cancer
colon
cancer
kaposi
sarcoma
ks
activ
area
investig
tumorigen
potenti
ep
receptor
form
mechanist
context
underli
chemotherapeut
potenti
nonsteroid
antiinflammatori
drug
nsaid
although
role
describ
sever
viral
associ
malign
biolog
signific
receptor
inflammatori
axi
extens
studi
kaposi
sarcomaassoci
herp
viru
associ
malign
ks
multifoc
endotheli
cell
tumor
primari
effus
lymphoma
pel
b
cellprolif
disord
purpos
review
summar
salient
find
delin
molecular
mechan
downstream
involv
secret
autocrin
paracrin
interact
ep
receptor
receptor
signal
regul
kshv
pathogenesi
latenc
kshv
infect
induc
secret
ep
receptor
activ
result
signal
cascad
modul
express
kshv
latenc
gene
latenc
associ
nuclear
viralfa
associ
via
death
domain
like
interferon
convert
enzymelikeinhibitori
protein
vflip
vflip
also
shown
crucial
mainten
activ
mutual
interdepend
interact
viral
protein
receptor
shown
play
key
role
biolog
mechan
involv
ks
pel
pathogenesi
blockag
apoptosi
cell
cycl
regul
transform
prolifer
angiogenesi
adhes
invas
immunesuppress
understand
axi
import
develop
new
safer
specif
therapeut
modal
ks
pel
addit
therapeut
target
ep
receptor
repres
ideal
target
pharmacolog
agent
analogu
blockersantagonist
possess
antineoplast
activ
without
report
gastroinarun
georg
paul
receiv
mdphd
abbrevi
cellular
inhibitor
apoptosi
creb
camp
respons
elementbind
cxc
motif
chemokin
ebv
epsteinbarr
viru
erk
extracellular
signalregul
kinas
fak
focal
adhes
kinas
htlv
human
lymphotrop
viru
inhibitor
dna
bind
ifng
interferong
ks
kaposi
sarcoma
kshv
kaposi
sarcoma
associatedherp
viru
latenc
associ
nuclear
antigen
lim
domain
lrmp
lymphoid
restrict
membran
protein
manganes
superoxid
dismutas
myc
vmyc
myelocytomatosi
viral
oncogen
homolog
nfat
nuclear
factor
activ
cell
nsaid
nonsteroid
antiinflammatori
drug
nsaid
nonsteroid
antiinflammatori
drug
pdgfb
platelet
deriv
growth
factor
b
pel
primari
effus
lymphoma
prostaglandin
phosphatidylinositid
ro
reactiv
oxygen
speci
stromal
cellderiv
signal
transduc
activ
transcript
tgfb
transform
growth
factor
beta
tolllik
receptor
vascularcel
adhes
molecul
vegf
vascular
endotheli
growth
factor
receptor
xiap
xlink
inhibitor
apoptosi
protein
translat
research
paul
et
al
testin
cardiovascular
toxic
observ
nsaid
translat
research
centuri
rudolf
virchow
first
propos
potenti
link
inflamm
cancer
base
observ
presenc
leukocyt
tumor
inflamm
physiolog
mechan
evolv
wound
heal
therefor
counterintuit
consid
oncogen
nevertheless
inflamm
doubleedg
sword
patholog
edg
promot
variou
aspect
tumorigenesi
deregul
cell
prolifer
migrat
angiogenesi
apoptosi
within
last
decad
multitud
studi
demonstr
abund
inflammatori
cell
macrophag
fibroblast
cancer
biopsi
b
role
proinflammatori
molecul
prostaglandin
leukotrien
transform
growth
factor
beta
tgfb
hypoxia
induc
alpha
vascular
endotheli
growth
factor
vegf
nitric
oxid
synthas
nitric
oxid
reactiv
oxygen
speci
ro
cytokin
chemokin
pathogenesi
sever
cancer
tumorigen
nurtur
properti
proinflammatori
tumor
microenviron
strongli
indic
inflamm
play
pathogen
role
sever
cancer
chronic
persist
inflamm
believ
play
import
role
pathogenesi
malign
depend
type
stage
cancer
physiolog
patholog
switch
inflamm
trigger
variou
factor
genom
instabl
epigenet
chang
somat
mutat
tumor
suppressor
oncogen
mediat
carcinogenesi
chronic
persist
infect
environment
stressor
pollut
role
tumor
virus
chronic
persist
inflamm
associ
carcinogenesi
demonstr
sever
malign
kaposi
sarcoma
associatedherp
viru
kaposi
sarcoma
ks
primari
effus
lymphoma
pel
epsteinbarr
viru
ebv
burkitt
lymphoma
nasopharyng
carcinoma
human
papillomaviru
hpv
cervic
cancer
hepat
b
hbv
hepat
c
virus
hcv
hepatocellular
cancer
human
tlymphotrop
viru
htlv
tcell
leukemia
virus
oblig
intracellular
parasit
use
host
protein
genom
replic
product
progeni
piraci
inflammatori
mechan
recur
theme
stori
infect
kshv
ebv
hcv
hpv
hbv
htlv
prolif
angiogen
immunesuppress
antiapoptot
nich
persist
inflamm
provid
purpos
review
highlight
salient
find
demonstr
kshv
use
pivot
receptor
mediat
inflammatori
axi
surviv
pathogenesi
therefor
play
crucial
role
kshvassoci
malign
cox
prostaglandinendoperoxid
synthas
catalyz
convers
arachidon
acid
aa
prostaglandin
convert
proinflammatori
lipid
metabolit
specif
enzym
play
crucial
role
divers
physiolog
function
platelet
aggreg
inhibit
gastrointestin
gi
acid
secret
regul
glomerular
function
labor
isoform
constitut
activ
promot
wherea
induc
promot
activ
stress
growth
factor
cytokin
infect
numer
studi
demonstr
induct
associ
inflammatori
pathway
pathogenesi
sever
cancer
colorect
prostat
lung
breast
cancer
well
sever
hematolog
malign
includ
chronic
lymphocyt
leukemia
hodgkin
nonhodgkin
lymphoma
nhl
multipl
myeloma
recent
year
investig
potent
chemotherapeut
target
due
wellstudi
anticanc
properti
nonsteroid
antiinflammatori
drug
nsaid
major
lipid
metabolit
implic
tumorigenesi
autocrin
paracrin
lipid
signal
induc
circul
halflif
approxim
second
normal
plasma
level
vari
pgml
exert
effect
rhodopsin
famili
g
protein
coupl
gpcr
eicosanoid
ep
receptor
name
ep
initi
signal
transduct
calcium
ca
cyclic
adenosin
monophosph
camp
protein
kinas
pka
phosphatidylinositid
ep
receptor
induct
associ
sever
oncogen
pathway
includ
src
pkc
nfkb
rasraf
erk
vegf
ppar
interleukin
il
therefor
form
mechanist
context
underli
divers
aspect
mediat
tumorigenesi
recent
year
link
ep
receptor
tumorigenesi
also
reveal
possibl
use
highli
specif
ep
receptor
antagonist
antagonist
antagonist
antagonist
anticanc
drug
infect
sever
virus
shown
regul
express
product
hbv
hepatocyt
hcv
cell
human
herpesviru
monocyt
human
cytomegaloviru
cmv
peripher
blood
mononuclear
cell
pbmc
smooth
muscl
cell
fibroblast
murin
gammaherpesviru
nih
cell
hiv
monocyt
pbmc
influenza
viru
pbmc
enteroviru
human
neuroblastoma
cell
dengu
viru
dendrit
cell
sever
acut
respiratori
syndrom
sar
associ
coronaviru
cell
theiler
murin
encephalomyel
viru
astrocyt
encephalomyocard
viru
macrophag
coxsacki
viru
monocyt
respiratori
syncyti
viru
macrophag
dendrit
cell
canin
distemp
viru
monocyt
implic
multitud
viral
mechan
genom
replic
hbv
cmv
htlv
gene
express
transmiss
htlv
cell
tropism
rhesu
cmv
cell
invas
cmv
cell
regul
hiv
even
identifi
viral
homologu
rhesu
cmv
reveal
signific
evolut
inflamm
mediat
viral
pathogenesi
among
herp
virus
studi
use
cox
inhibitor
shown
role
pathway
replic
success
lytic
cycl
hsv
cmv
howev
role
extens
molecular
framework
underli
receptor
inflammatori
axi
herp
viral
latenc
describ
kshvassoci
malign
ks
pel
kshv
associ
diseas
group
herp
viru
famili
etiolog
agent
underli
ks
pel
multicentr
castleman
diseas
like
herp
virus
kshv
life
cycl
character
phase
latent
lytic
cycl
infect
kshv
enter
latenc
phase
viru
remain
evas
transform
infect
cell
stabl
reservoir
lytic
cycl
result
replic
viral
genom
product
new
viral
progeni
life
cycl
associ
distinct
viral
protein
gene
express
profil
ks
pel
multicentr
castleman
diseas
biopsi
shown
major
tumor
cell
express
latenc
transcript
tumor
cell
undergo
lytic
cycl
given
time
point
stage
life
cycl
implic
pathogenesi
kshv
associ
diseas
although
specif
treatment
target
kshv
associ
diseas
highli
activ
antiretrovir
therapi
haart
consequ
immun
reconstitut
demonstr
benefici
treat
aidsk
ks
epidemiolog
ks
classifi
subgroup
classic
ks
describ
moritz
kaposi
elderli
men
mediterranean
origin
endem
ks
subsaharan
africa
epidem
ks
aid
patient
ks
form
common
aid
associ
malign
transplant
defin
ks
patholog
ks
multifoc
angioprolif
tumor
vascular
natur
character
extravascular
erythrocyt
spindl
shape
cell
endotheli
origin
inflammatori
cell
monocyt
fibroblast
neutrophil
lymphocyt
interspers
narrow
irregular
angul
slit
within
proinflammatori
angiogen
microenviron
fatal
ks
often
due
system
spread
respiratori
system
gastrointestin
tract
lymph
node
organ
pel
pel
rare
yet
aggress
form
b
cell
lymphoma
account
aid
associ
nhl
prognosi
less
month
pel
character
primari
lymphomat
aggreg
within
major
bodi
caviti
pleura
pericardium
peritoneum
patholog
pel
cell
show
vari
phenotyp
immunoblast
plasmablast
anaplast
propos
lie
prob
cell
plasma
cell
lineag
pel
cell
character
b
cell
transform
persist
kshv
infect
consist
multipl
copi
order
copiescel
episom
kshv
genom
latent
viral
gene
express
pattern
involv
latenc
associ
nuclear
antigen
lana
viral
homologu
host
protein
cyclin
vcyclin
fliceinhibitori
protein
viralfliceinhibitori
protein
vflip
premicrorna
transcript
encod
viral
microrna
well
homologu
also
express
pel
cell
pel
cell
express
varieti
cell
surfac
marker
differ
stage
b
cell
develop
activ
marker
sever
plasma
cell
marker
includ
devoid
b
cell
marker
kshv
latenc
inflamm
kshv
latenc
propos
symphoni
wellorchestr
interact
viral
host
protein
lead
transform
infect
cell
viral
surviv
success
genom
replic
immun
evas
host
viral
protein
interact
initi
establish
kshv
infect
surviv
establish
mainten
latenc
progress
patholog
ks
pel
condit
persist
select
pressur
aid
relat
transplant
associ
immun
suppress
decreas
incid
ks
posthaart
therapi
aid
patient
suggest
scenario
host
mechan
underli
establish
mainten
kshv
infect
kshv
associ
malign
includ
cell
signal
antiapoptosi
angiogenesi
immun
modul
cell
prolifer
mediat
cytokin
growth
factor
inflammatori
molecul
thu
identif
molecul
use
kshv
latenc
program
enabl
us
delin
pathogenesi
ks
pel
well
studi
naranatt
et
al
sharmawalia
et
al
first
indic
induct
de
novo
kshv
infect
human
microvascular
dermal
endotheli
hmvecd
cell
studi
introduc
novel
idea
regard
function
signific
within
context
kshv
latenc
program
kshv
infect
induc
supplement
revers
inhibitor
mediat
downregul
latenc
gene
therefor
studi
first
time
gener
hypothesi
kshv
infect
induc
crucial
establish
mainten
latenc
consid
oncogen
potenc
activ
inflammatori
mechan
proinflammatori
mechan
underli
ks
pel
pathogenesi
well
character
role
viral
tumor
burkitt
lymphoma
cervic
cancer
studi
sharmawalia
et
al
sever
gene
array
studi
demonstr
induct
multitud
malign
premalign
human
cancer
lesion
progress
increas
express
stage
cancer
advanc
demonstr
doubl
stain
spindl
shape
cell
tissu
microarray
human
ks
section
eye
orbit
tonsil
mouth
small
bowel
sharmawalia
et
al
similarli
abund
express
mpge
observ
human
ks
biopsi
georg
paul
et
al
collect
find
corrobor
earlier
vitro
observ
first
detail
investig
ep
receptor
human
ks
first
detail
investig
ep
receptor
human
ks
biopsi
sever
possibl
mechan
underli
receptor
induct
ks
lesion
sever
persist
kshv
infect
persist
chronic
inflamm
patholog
stress
chronic
persist
infect
inflamm
ks
patient
associ
cancer
attribut
induc
promot
activ
stress
infect
inflamm
role
infect
mediat
signal
induct
demonstr
sever
virus
cmv
ro
campnuclear
factor
activ
cell
nfat
hbv
ca
ro
campnfat
hcv
ca
ro
encephalomyocard
viru
emcv
nfkbmapkcjun
ntermin
enteroviru
respons
elementbind
creb
sar
nfkbcebp
dengu
viru
examin
whether
similar
molecular
mechan
work
induct
ks
demonstr
de
novo
kshv
infect
exogen
upregul
promot
activ
src
pkc
focal
adhes
kinas
jnk
camp
pka
nfkb
promot
analysi
use
promot
delet
construct
mutat
report
construct
identifi
transcript
factor
creb
nfat
cell
downstream
signal
cascad
synergist
modul
promot
activ
multitud
similar
pathway
also
activ
earli
kshv
bind
infect
microtubul
nfkb
fak
vegf
lipid
raft
indic
kshv
entri
associ
signal
transduct
event
infectioninduc
secret
work
concert
activ
promot
howev
presenc
strong
express
ks
lesion
strongli
suggest
exist
viral
mechan
sustain
express
post
establish
kshv
latenc
induct
demonstr
viral
protein
well
tax
protein
hiv
hbx
hbv
cov
nprotein
sar
viru
kshv
latenc
protein
vflip
lytic
protein
kshv
g
proteincoupl
receptor
constitut
activ
lytic
phase
protein
signific
homolog
human
receptor
viral
protein
propos
capabl
induc
vflip
shown
induc
studi
recent
delin
detail
mechanist
aspect
vflip
mediat
express
mediat
nfkb
rsk
transcript
factor
creb
addit
vflip
activ
express
secret
demonstr
part
signal
loop
requir
vflipinduc
nfkb
activ
induct
lytic
protein
kshv
g
proteincoupl
receptor
also
rais
question
whether
play
role
lytic
cycl
still
investig
induct
ep
receptor
viral
infect
larg
unexplor
arena
studi
georg
paul
et
al
demonstr
protein
level
significantli
upregul
longtermkshvinfect
endotheli
cell
observ
upregul
receptor
de
novo
kshv
infect
hmvecd
cell
ep
receptor
present
endotheli
cell
gener
homeostat
function
gi
mucos
protect
howev
patholog
upregul
characterist
mani
malign
colorect
cancer
therefor
work
georg
paul
et
al
georg
paul
et
al
strongli
suggest
role
ks
pathogenesi
work
requir
character
signal
transcript
mechan
underli
induct
ep
receptor
express
pathogenesi
ks
lesion
consist
spindl
shape
endotheli
cell
neovascular
structur
inflammatori
cell
profoundli
influenc
growth
factor
gf
proinflammatori
cytokin
ic
angiogen
factor
af
basic
acid
fibroblast
growth
factor
bfgf
afgf
granulocytemonocyt
coloni
stimul
factor
gmcsf
platelet
deriv
growth
factor
b
pdgfb
vegf
interferong
ifng
tumor
necrosi
factora
tnfa
angiogenin
heme
tgfb
adhes
molecul
like
intercellularvascularcel
adhes
molecul
matrix
metalloproteinas
mmp
like
combin
effect
molecul
contribut
differ
aspect
ks
pathogenesi
neovascular
angiogenesi
mainten
kshv
latenc
metastasi
wherea
mechan
underli
sustain
activ
molecul
still
activ
area
investig
cell
migrat
metastasi
character
biolog
signific
kshv
infect
cell
demonstr
pharmacolog
small
interf
rna
base
inhibit
downregul
format
intric
vitro
capillari
tube
cell
adhes
cell
invas
capabl
hmvecd
cell
ad
addit
dimens
observ
demonstr
inhibit
could
downregul
vflip
mediat
pathogen
mechan
ep
receptor
propos
tumorigen
workhors
ep
receptor
gpcr
wellcharacter
pathogenesi
multitud
cancer
melanoma
breast
cancer
colon
cancer
contribut
prolifer
immunosuppress
angiogenesi
invas
block
apoptosi
activ
src
kinas
camp
creb
rasraf
nfkb
egfr
ppardb
pathway
role
src
kinas
akt
erk
nfkb
earli
event
kshv
infect
establish
latenc
wellcharacter
collect
studi
sharmawalia
et
al
demonstr
pathway
downstream
activ
viral
nonvir
mechan
particip
enrich
tumor
microenviron
consequ
variou
patholog
process
underli
ks
endotheli
transform
neovascular
metastasi
howev
pathway
downstream
result
activ
src
camp
akt
rasraf
erk
nfkb
egfr
pathway
form
first
line
signal
transduc
molecular
avalanch
eventu
result
induct
ic
gf
af
mmp
still
activ
area
investig
identifi
involv
ep
receptor
induct
variou
signal
molecul
downstream
kshv
latenc
program
specif
receptor
implic
activ
ca
nfkb
receptor
pkczl
nfkb
activ
receptor
pkczl
erk
erk
nfkb
activ
longterminfect
cell
antagonist
could
also
downregul
express
major
kshv
latenc
gene
inhibit
induct
ca
phosphoryl
src
pkczl
nfkb
signal
signal
molecul
regul
promot
induc
promot
activ
found
similar
ep
receptor
mediat
signal
transduct
pathway
latent
infect
endotheli
cell
gene
express
secret
also
significantli
downregul
pharmacolog
inhibit
receptor
observ
implic
first
time
role
ep
receptor
form
herpesviru
latenc
thu
substanti
earlier
observ
sharmawalia
et
al
elucid
signal
transduct
network
ep
receptor
initi
kshv
infect
mediat
activ
secret
tumor
microenviron
activ
ep
receptor
mediat
signal
cascad
paracrin
autocrin
fashion
exert
effect
express
consequ
selfsustain
posit
feedback
loop
network
kshv
protein
proinflammatori
pathway
regul
receptor
creat
viral
infect
recent
work
dupuy
et
al
substanti
role
ep
receptor
ks
pathogenesi
report
use
inhibitor
attract
approach
treat
aggress
ks
could
restor
activ
surviv
tumoricid
nk
cell
studi
provid
strong
evid
downmodul
mediat
inflammatori
known
releas
ks
cell
also
show
act
prevent
activ
nk
cell
role
ep
receptor
induct
sever
kshv
associ
signal
network
consequ
variou
pathogen
mechan
indic
kshv
subvert
receptor
mediat
protumorigen
signal
pathway
sustain
viral
host
gene
express
howev
studi
also
demonstr
neither
chemic
inhibitor
indomethacin
could
complet
abolish
induct
ic
gf
mmp
af
indic
presenc
multitud
host
molecul
like
subvert
kshv
infect
pel
compris
b
cell
transform
kshv
latent
infect
studi
propos
cumul
interdepend
vital
express
kshv
latenc
gene
proinflammatori
environ
manipul
canon
anticanc
host
defens
machineri
metamorphosi
pel
neoplasia
mechanist
role
hematolog
malign
kshv
latenc
program
endotheli
model
system
well
establish
studi
paul
et
al
first
time
delin
role
pel
pathogenesi
use
inhibitor
nimesulid
nimesulid
downregul
kshv
latenc
gene
vflip
induc
cell
cycl
arrest
apoptosi
activ
tumor
suppressor
pathway
downregul
cell
surviv
kinas
angiogen
factor
vegfc
pel
cell
multifunct
protein
major
marker
kshv
latenc
divers
role
kshv
latenc
includ
mainten
viral
episom
host
gene
manipul
recruit
chromatin
bind
protein
cell
cycl
regul
blockad
apoptosi
downregul
rb
vflip
one
key
kshv
latent
protein
perform
multipl
function
upregul
induct
nfkb
spindl
infect
endotheli
cell
modul
cell
prolifer
immun
evas
pel
consist
transform
b
cell
vitro
clonogen
properti
attribut
multitud
molecul
key
observ
paul
et
al
inhibit
coloni
format
capac
pel
cell
nimesulid
encapsul
patholog
consequ
inhibit
mediat
latenc
blockad
arrest
apoptosi
induct
pel
cell
nimesulid
mediat
prolifer
arrest
alter
cell
cycl
profil
apoptosi
pel
cell
could
relat
downregul
kshv
latenc
protein
vflip
result
blockad
viru
induc
prosurviv
mechan
pel
howev
consid
oncogen
potenti
receptor
cancer
system
also
import
pel
pathogenesi
antigrowth
effect
nimesulid
could
also
due
drug
effect
pathway
well
independ
viral
protein
nsaid
consist
inhibitor
aspirin
indomethacin
diclofenac
specif
inhibitor
nimesulid
coxib
celecoxib
rofecoxib
valdecoxib
lumiracoxib
famili
specif
drug
coxib
gain
popular
notorieti
last
decad
potent
antipyret
analges
effect
numer
trial
strongli
suggest
increas
cardiovascular
event
chronic
use
rofecoxib
celecoxib
respect
chemotherapeut
perspect
consid
sever
side
effect
exist
antipel
drug
regimen
provid
specif
cure
pel
goal
identifi
drug
potent
antikshv
anticanc
activ
least
side
effect
sever
line
work
current
underway
develop
antipel
therapi
base
pel
pathogenesi
proapoptot
agent
bortezomib
azidothymidin
antiprolif
antibiot
rapamycin
activ
antivir
compound
cidofovir
ifna
reactiv
oxygen
speci
hydrogen
peroxid
activ
unfold
protein
respons
kshv
latenc
gene
block
agent
glycyrrhiz
acid
small
rna
transcript
wellestablish
tumorigen
potenti
receptor
pathway
avail
wellcharacter
ep
receptor
antagonist
food
drug
administrationapprov
inhibitor
known
anticanc
effect
demonstr
receptor
kshv
latenc
correl
express
poor
nhl
prognosi
provid
excel
context
examin
chemotherapeut
potenti
nsaid
treat
pel
paul
et
al
studi
paul
et
al
work
georg
paul
et
al
examin
chemotherapeut
potenti
nimesulid
celecoxib
pel
sever
nhl
cell
line
respect
nimesulid
wellcharacter
inhibitor
known
anticanc
properti
alreadi
prescrib
approxim
million
peopl
differ
countri
sinc
introduct
celecoxib
introduc
sever
line
work
strongli
suggest
anticanc
effect
nimesulid
celecoxib
celecoxib
anticanc
effect
propos
due
inhibit
noncox
depend
antigrowth
effect
nimesulid
could
induc
signific
prolifer
arrest
multitud
kshvbjab
lcl
raji
kshvebv
louk
ramo
akataebv
nhl
cell
line
select
potenc
ebvcel
line
suggest
prolifer
arrest
induc
nimesulid
nhl
cell
line
test
due
gener
antiprolif
effect
nsaid
tumor
cell
line
work
paul
et
al
celecoxib
signific
antiprolif
effect
kshvebv
bjab
cell
line
chemotherapeut
potenti
ep
receptor
antagonist
nhl
still
unexamin
studi
paul
et
al
previou
work
examin
role
mediat
tumorigenesi
propos
combin
lower
dose
inhibitor
ep
receptor
antagonist
reduc
advers
effect
nsaid
gi
cardiovascular
toxic
howev
potenti
synergist
anticanc
effect
combin
blockad
ep
receptor
still
unexamin
current
studi
paul
et
al
demonstr
combin
mm
celecoxib
antagonist
gw
antagonist
potenti
proapoptot
effect
celecoxib
cell
strongli
suggest
chemotherapeut
potenti
novel
paradigm
base
concurr
inhibit
ep
receptor
obtain
potent
addit
anticanc
effect
studi
show
simultan
inhibit
receptor
modul
sever
class
gene
propos
import
kshv
ebv
associ
lymphoma
pathogenesi
includ
tumor
suppressor
gene
belong
lymphoma
surviv
cell
cycl
arrest
cell
adhes
apoptosi
signal
epigenet
regul
furthermor
studi
also
show
activ
sever
host
gene
propos
downregul
either
kshvebv
infect
respect
viral
protein
chemokin
cxc
motif
receptor
lim
domain
vmyc
myelocytomatosi
viral
oncogen
homolog
myc
tolllik
receptor
inhibitor
dna
bind
antigen
identifi
monoclon
antibodi
atm
lymphoidrestrict
membran
protein
lrmp
membran
metalloendopeptidas
mme
glutathion
stransferas
pi
overal
studi
paul
et
al
paul
et
al
propos
anticanc
effect
concurr
target
receptor
due
simultan
inhibit
viral
nonvir
mediat
tumorigen
mechan
act
multipl
level
key
aspect
chronic
inflamm
oncogenesi
attribut
inflamm
susten
drive
factor
activ
secret
mediat
function
autocrin
paracrin
signal
interest
find
studi
georg
paul
et
al
downregul
gene
express
secret
antagonist
indic
posit
feedback
loop
mediat
receptor
signal
simultan
regul
express
mechanist
stabil
messeng
rna
mrna
transcript
shown
mediat
depend
signal
act
sequenc
utr
region
mrna
interestingli
kshv
protein
kaposin
b
also
shown
stabil
mrna
transcript
utr
sequenc
signal
studi
critic
fulli
understand
pathway
examin
effect
ep
receptor
antagon
gene
express
kaposin
b
cytokin
activ
protein
level
multipl
promot
lti
ltc
ltd
identifi
kshv
latenc
locu
account
transcript
vflip
vcyclin
viral
microrna
kaposin
therefor
induct
promot
ep
receptor
agonist
also
rais
question
whether
ep
receptor
could
kshv
interact
receptor
bind
enter
target
cell
induc
varieti
overlap
cell
signal
cascad
extracellular
signalregul
kinas
phosphatidylinositid
rho
famili
gtpase
focal
adhes
kinas
src
nuclear
factor
kappalightchainenhanc
activ
b
cell
protein
kinas
c
transcript
factor
cfo
cjun
cmyc
signal
transduc
activ
transcript
earli
infect
kshv
infect
via
induct
signal
pathway
also
reprogram
modul
variou
host
cell
gene
one
molecul
angiogen
stress
respons
gene
kshv
infect
induc
led
secret
inflammatori
metabolit
varieti
transcript
factor
nfkb
nfat
cre
stimul
express
kshv
entri
associ
signal
cascad
involv
fak
src
jnk
activ
transcript
factor
nfat
cyclic
adenosin
monophosph
respons
elementbind
creb
stimul
gene
express
secret
exert
effect
famili
gproteincoupl
rhodopsintyp
ep
receptor
along
detect
human
ks
lesion
besid
manipul
host
gene
kshv
establish
latenc
host
cell
observ
increas
express
viral
latent
gene
latenc
associ
nuclear
antigen
lana
vflip
microenviron
infect
cell
function
paracrin
autocrin
fashion
augment
goal
establish
maintain
express
viral
latenc
protein
ca
src
nkkb
mediat
signal
cascad
ep
receptor
antagonist
downregul
express
inhibit
ca
psrc
ppkczl
pnfkb
exogen
ep
receptor
agonist
induc
promot
activ
transcript
factor
specif
protein
octam
transcript
octam
transcript
ccaatenhancerbind
protein
cjun
collect
studi
demonstr
kshv
pirat
proinflammatori
receptor
maintain
latenc
host
cell
convers
viral
latenc
protein
vflip
mediat
signal
sustain
express
secret
kshvoncogen
protein
vflip
induc
enhanc
transform
abil
anchorag
independ
coloni
format
metastat
potenti
matrix
metalloproteinas
mmp
inflammatori
phenotyp
inflammatori
cytokin
monocyt
chemotact
rant
groab
interleukin
interleukin
inflammationrel
adhes
molecul
chemokin
promot
anoiki
resist
prolong
infect
cell
surviv
cell
surviv
gene
cellular
activ
latenc
promot
well
elucid
mechan
would
provid
comprehens
perspect
kshv
util
ep
receptor
regul
latenc
studi
promot
delet
construct
identifi
respons
region
kshv
latenc
locu
kshv
latenc
locu
known
regul
ctcf
sever
unidentifi
transcript
factor
tf
among
tf
identifi
within
minim
region
promot
requir
mediat
promot
activ
sever
transcript
factor
could
potenti
stimul
ep
receptor
cebp
cjun
function
signific
tf
induc
promot
specif
bind
site
influenc
ep
receptor
tf
remain
determin
key
concept
introduc
georg
paul
et
al
role
receptor
induc
ca
signal
kshv
latenc
program
studi
identifi
specif
type
calcium
signal
induc
receptor
longterminfect
cell
lead
sever
question
effector
molecul
transcript
factor
activ
calcium
signal
one
intrigu
find
studi
paul
et
al
downregul
vdr
express
nimesulid
pel
cell
vdr
uniqu
overexpress
pel
cell
line
unlik
nhl
role
transmembran
proteoglycan
cell
migrat
signal
signific
syndecan
secret
proteoglycan
signal
key
aspect
oncogenesi
vdr
natur
receptor
induct
vdr
associ
chromatin
remodel
also
propos
increas
risk
esophag
squamou
prostat
pancreat
cancer
activ
osteopontin
rangtpas
channel
protein
involv
transport
water
glycerol
atp
gener
lung
adenocarcinoma
colorect
cancer
squamou
cell
carcinoma
propos
play
role
promot
cell
migrat
actin
depolymer
atp
gener
link
express
vdr
within
context
pel
rais
sever
import
question
role
proteoglycan
mediat
signal
chromatin
remodel
atp
metabol
pel
might
contribut
pel
pathogenesi
novel
signal
network
overal
studi
review
provid
glimps
molecular
framework
underli
angiogen
stress
respons
proinflammatori
protein
infam
lipid
metabolit
ep
receptor
establish
mainten
kshv
latenc
therefor
implic
inhibitor
ep
receptor
antagonist
potent
chemotherapeut
modal
treat
kshv
relat
lymphoma
fig
thu
studi
add
novel
paradigm
pathogenesi
kshv
associ
diseas
rais
sever
question
could
expand
understand
role
chronic
persist
inflamm
ks
pel
current
nhl
fifth
common
cancer
unit
state
account
cancer
annual
incid
increas
keep
mind
ultim
aim
cancer
treatment
inhibit
growth
precancer
cancer
cell
without
affect
normal
cell
could
studi
review
suggest
antiprolif
effect
inhibitor
ep
receptor
antagonist
variou
nhl
cell
line
data
eman
inhibitor
apoptosi
cellular
inhibitor
apoptosi
xlink
inhibitor
apoptosi
protein
superoxid
dismutas
bcell
lymphoma
immedi
earli
respons
gene
antiapoptot
protein
bcell
lymphoma
myeloid
leukemia
cell
differenti
protein
bcell
lymphomaextra
larg
interact
mediat
cell
death
bax
transloc
cytoplasm
cell
surviv
kinas
nfkb
k
akt
addit
kshvinduc
regul
multipl
event
involv
ks
pathogenesi
secret
proinflammatori
cytokin
growth
factor
alpha
beta
subunit
beta
interleukin
lymphocyt
matur
factor
tumor
necrosi
factor
alpha
interferon
gammainduc
protein
neutrophilactiv
oncostatin
thrombopoeitin
fibroblast
growth
factor
fractalkin
insulinlik
growth
factorbind
protein
osteoprotegerin
angiogen
factor
vascular
endotheli
growth
factor
vegf
ac
invas
factor
blockad
reduc
latent
infect
endotheli
cell
adhesioninvas
surviv
prolifer
shorten
phase
arrest
infect
cell
phase
similar
downstream
effect
ks
pathogenesi
establish
contribut
pel
pathogenesi
via
viral
gene
independ
depend
pathway
blockad
reduc
kshv
latent
vflip
gene
express
disrupt
protein
complex
activ
tumorsuppressor
pathway
pel
cell
contribut
prosurviv
mechan
pel
cell
via
regul
cell
surviv
pakt
cell
cycl
apoptosi
blockad
cyclin
ea
angiogenesi
vegfc
transform
potenti
coloni
form
capac
pel
cell
modul
pel
defin
gene
receptor
collect
observ
provid
comprehens
molecular
framework
link
ks
pel
pathogenesi
identifi
chemotherapeut
potenti
target
axi
treat
ks
pel
vitro
studi
valuabl
inform
requir
examin
ongo
studi
use
vitro
angiogen
model
vivo
nude
mice
model
valid
inhibitor
ep
receptor
antagonist
novel
therapeut
target
latent
kshv
infect
viral
pathogenesi
associ
diseas
ks
pel
author
thank
keith
philibert
critic
read
review
